Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 8.91% and Operating profit at 68.99% over the last 5 years
2
The company has declared Negative results for the last 5 consecutive quarters
3
With ROE of 12.81%, it has a fair valuation with a 2.47 Price to Book Value
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 6,219 Million (Mid Cap)
19.00
NA
2.22%
-0.31
12.81%
2.47
Revenue and Profits:
Net Sales:
908 Million
(Quarterly Results - Jun 2025)
Net Profit:
111 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.08%
0%
-12.08%
6 Months
-9.76%
0%
-9.76%
1 Year
-15.67%
0%
-15.67%
2 Years
-46.63%
0%
-46.63%
3 Years
-31.97%
0%
-31.97%
4 Years
-37.27%
0%
-37.27%
5 Years
35.86%
0%
35.86%
Jianmin Pharmaceutical Group Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.91%
EBIT Growth (5y)
68.99%
EBIT to Interest (avg)
52.74
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.36
Sales to Capital Employed (avg)
1.45
Tax Ratio
14.91%
Dividend Payout Ratio
38.12%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
14.21%
ROE (avg)
18.68%
Valuation key factors
Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
2.47
EV to EBIT
34.99
EV to EBITDA
23.88
EV to Capital Employed
3.13
EV to Sales
1.66
PEG Ratio
NA
Dividend Yield
2.22%
ROCE (Latest)
8.94%
ROE (Latest)
12.81%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
908.00
886.40
2.44%
Operating Profit (PBDIT) excl Other Income
83.50
96.80
-13.74%
Interest
2.10
3.20
-34.38%
Exceptional Items
7.70
7.10
8.45%
Consolidate Net Profit
111.30
111.00
0.27%
Operating Profit Margin (Excl OI)
73.00%
89.70%
-1.67%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 2.44% vs 43.48% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 0.27% vs 156.94% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
3,482.70
4,184.10
-16.76%
Operating Profit (PBDIT) excl Other Income
180.60
371.70
-51.41%
Interest
14.00
4.80
191.67%
Exceptional Items
27.90
5.80
381.03%
Consolidate Net Profit
367.70
523.20
-29.72%
Operating Profit Margin (Excl OI)
31.60%
74.70%
-4.31%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -16.76% vs 15.70% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -29.72% vs 28.87% in Dec 2023
About Jianmin Pharmaceutical Group Co., Ltd. 
Jianmin Pharmaceutical Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






